Abiopharma

RAPPORT THERAPEUTICS, INC. (RAPP)

Symbol	RAPP
Name	RAPPORT THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	1325 BOYLSTON STREET,,SUITE 401, BOSTON, Massachusetts, 02215, United States
Telephone	857-321-8020
Fax	—
Email	—
Website	https://www.rapportrx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0002012593
Description	Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. Additional info from NASDAQ: Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

2026-06-29 20:45

📋 Abraham N. Ceesay (Officer) plans to sell 99K shares of RAPPORT THERAPEUTICS, INC. (at $40.39 each, total $4.0M) Filed: Jun 29, 2026 | ID: 000411

2026-06-10 21:57

MARAGANORE JOHN 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266155

2026-06-10 21:52

PEREZ ROBERT J 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266147

2026-06-10 21:28

Silva Paul M 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266099

2026-06-10 21:26

HEALY JAMES 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266095

2026-06-10 21:25

Huber Reid M 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266090

2026-06-10 21:24

Young Wendy B. 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266086

2026-06-10 21:23

Sanchez Ramiro 🟢 acquired 15.2K shares (1 derivative) of Rapport Therapeutics, Inc. (RAPP) at $35.21 Transaction Date: Jun 10, 2026 | Filing ID: 266080

2026-06-10 20:12

(99% Neutral) RAPPORT THERAPEUTICS, INC. (RAPP) Files Form 8-K

2026-05-28 20:15

Third Rock Ventures V, L.P. 🔴 sold 18.6K shares of Rapport Therapeutics, Inc. (RAPP) at $40.05 Transaction Date: May 26, 2026 | Filing ID: 245259

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07563881	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With …	Phase3	Focal Seizure	Recruiting	2026-06-05	2029-09-01	ClinicalTrials.gov
NCT07594119	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With …	Phase3	Focal Seizure	Recruiting	2026-06-01	2029-09-01	ClinicalTrials.gov
NCT07219407	A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Foc…	Phase2	Focal Epilepsy	Recruiting	2025-12-15	2028-02-03	ClinicalTrials.gov
NCT07046494	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With …	Phase2	Bipolar 1 Disorder	Recruiting	2025-07-25	2026-11-01	ClinicalTrials.gov
NCT06377930	Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With …	Phase2	Focal Onset Seizures	Completed	2024-10-10	2025-09-26	ClinicalTrials.gov

Total clinical trials: 5

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07594119
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07594119
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	RECRUITING	NCT07563881
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
Placebo	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE3	Focal Seizure	NOT_YET_RECRUITING	NCT07563881
RAP-219	Other	Phase PHASE2	Focal Epilepsy	RECRUITING	NCT07219407
RAP-219	Other	Phase PHASE2	Focal Onset Seizures	COMPLETED	NCT06377930
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	Other	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
Placebo	OTHER	Phase PHASE2	Bipolar 1 Disorder	RECRUITING	NCT07046494
RAP-219	DRUG	Phase PHASE2	Focal Epilepsy	RECRUITING	NCT07219407

Total products: 180